Kringle Pharma: strengthens its intellectual property portfolio with the formulation patent in Europe.


Press release

December 29, 2021

Kringle Pharma strengthens its intellectual property portfolio with the formulation patent in Europe

Kringle Pharma, Inc. (headquartered in Ibaraki, Osaka; President and CEO, Kiichi Adachi; “KRINGLE”), an advanced clinical biopharmaceutical company, today announces that the European Patent Office has issued the Patent No. EP3192524, entitled “PREPARATION OF HGF SUITABLE FOR TREATMENT OF NERVOUS DISEASES”. This patent covers proprietary formulations of pharmaceuticals containing recombinant human hepatocyte growth factor (HGF). A drug product based on the patented formulation has been used in ongoing clinical studies including phase 3 in acute spinal cord injury and phase 2 in amyotrophic lateral sclerosis (ALS). In addition, the Phase 1/2 vocal cord scar study was completed with the same investigational drug to be administered locally to the vocal cords (Hirano et al., J Tissue Eng Regen Med. 2018; 12 (4): 1031-1038). Therefore, the patented drug formulation can be used not only for neuronal diseases, but also for other incurable diseases such as vocal cord scar, which forms the basis for expanding target indications for HGF treatment. . This patent has already been granted in the United States, Japan, Canada and Korea, further strengthening Kringle’s intellectual property position globally.

About hepatocyte growth factor (HGF)

HGF was initially discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs, including including not only the liver, but also the kidneys, heart, lungs, nerve tissue and skin. The therapeutic effects of administration of HGF in model animals of untreatable diseases have been reported in numerous scientific papers, and expectations for HGF as a novel therapeutic agent for intractable diseases are increasing.

About Kringle Pharma, Inc.

Kringle Pharma is an advanced clinical biopharmaceutical company established in December 2001 to develop new biologics based on HGF. Currently, Kringle’s clinical programs with recombinant human HGF are: 1) Ongoing Phase 3 in Acute Spinal Cord Injury, 2) Ongoing Investigator Initiated Phase 2 in ALS, 3) Phase 2/3 in preparation in the scar of the vocal cords, and 4) Phase 1a and 1b completed in acute renal failure. Kringle’s mission is to contribute to societal and global healthcare through the continued research, development and commercialization of the HGF drug for patients with incurable diseases.

For more information please contact??

Daichika Hayata

Director, Pharmaceutical Development

Kringle Pharma, Inc.


Comments are closed.